Publication:
Topkan's CARWL index efficiently predicts the radiation-induced tooth loss rates in radically treated locally advanced nasopharyngeal cancer patients

Placeholder

Organizational Units

Program

KU-Authors

Selek, Uğur
Durankuş, Nilüfer Kılıç
Şenyürek, Şükran

KU Authors

Co-Authors

Somay, Efsun
Topkan, Erkan
Bascil, Sibel
Ozturk, Duriye

Advisor

Publication Date

Language

Journal Title

Journal ISSN

Volume Title

Abstract

Purpose To assess the usefulness of the novel CARWL index in predicting radiation-induced tooth loss (RITL) rates in locally advanced nasopharyngeal cancer (LA-NPC) patients undergoing concurrent chemoradiotherapy (C-CRT). Methods The study retrospectively examined data from 323 LA-NPC patients. The patients were divided into two groups based on cutoff values for CAR and weight loss (WL). The ideal cutoff for RITL was 3.0 g/dL [AUC: 83.0%, sensitivity: 83.6%, specificity: 81.4%, J-index: 0.650]. CARWL index was created by combining pretreatment CAR and WL status (WL <= 5.0% vs > 5.0%, resulting in four groups: Group 1: CAR < 3.0 and WL <= 5.0%, Group 2: CAR < 3.0 and WL > 5.0%, Group 3: CAR >= 3.0 and WL <= 5.0%, and Group 4: CAR > 3.0 and WL > 5.0%. Results RITL was diagnosed in 67.2% of patients. Since the RITL rates of Groups 2 and 3 were statistically indistinguishable, we combined them and created the three-tiered CARWL score groups: CARWL-0: CAR < 3.0 and WL <= 5.0%;CARWL-1: CAR < 3.0 and WL > 5.0%, or CAR >= 3.0 and WL <= 5.0%;and CARWL-2: CAR > 3.0 and WL > 5.0%. Comparative analysis revealed that the RITL rates gradually and significantly increased from CARWL-0 to CARWL-2 score groups (49.4% vs 64.7% vs 83.0%;P <0.001) despite similar baseline disease and patient characteristics. Results of the multivariate analysis showed that higher CARWL score groups were independent and significant predictors of increased RITL rates (p < 0.001). Conclusion Present results suggest that the novel CARWL index is a reliable biomarker for predicting RITL incidence in LA-NPC patients.

Source:

Technology in Cancer Research and Treatment

Publisher:

Sage

Keywords:

Subject

Oncology

Citation

Endorsement

Review

Supplemented By

Referenced By

Copyrights Note

0

Views

0

Downloads

View PlumX Details